content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">As filed with the Securities and Exchange Commission
  on November 22, 2021</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Registration No. 333-</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1.5pt; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES<BR>
  SECURITIES AND EXCHANGE COMMISSION<BR>
  Washington, D.C. 20549<BR>
  ____________________________<BR>
  <BR>
  FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REGISTRATION STATEMENT<BR>
  UNDER<BR>
  THE SECURITIES ACT OF 1933<BR>
  ____________________________<BR>
  <BR>
  PLX PHARMA INC.<BR>
  </B>(Exact name of registrant as specified in its charter)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 50%; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Delaware</B><BR>
  (State or other jurisdiction of<BR>
  incorporation or organization)</TD>
      <TD STYLE="width: 50%; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>46-4995704</B><BR>
  (I.R.S. Employer Identification Number)</TD></TR>
    </TABLE>
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;<B>PLx Pharma Inc.<BR>
  9 Fishers Lane, Suite E</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Sparta, New Jersey 07871</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>____________________________</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PLX PHARMA INC. 2018 INCENTIVE PLAN</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PLX PHARMA INC. 2015 OMNIBUS INCENTIVE PLAN</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Full title of the plans)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>____________________________</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Natasha Giordano</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>President and Chief Executive Officer</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PLx Pharma Inc.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>9 Fishers Lane, Suite E</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Sparta, New Jersey 07871</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(973) 409-6541</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Name, address and telephone number, including area
  code, of agent for service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>____________________________</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><I>With a copy to:</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Robert Friedman, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Olshan Frome Wolosky LLP</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>1325 Avenue of the Americas</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>New York, New York 10019</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Telephone: (212) 451-2300</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>____________________________</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
  See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company&rdquo;
  and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">TABLE OF CONTENTS</A>&nbsp;</P></DIV>
      <!-- Field: /Page -->
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 6%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-indent: 0in">&nbsp;</TD>
      <TD STYLE="width: 41%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-indent: 0in">Large accelerated filer&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT></TD>
      <TD STYLE="width: 53%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-indent: 0in">Accelerated filer&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Non-accelerated filer&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#253;</FONT></TD>
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Smaller reporting company&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#253;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">Emerging growth company&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT></TD>
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">&nbsp;</TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">If an emerging growth company, indicate by check mark
  if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
  provided pursuant to Section 7(a)(2)(B) of the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">____________________________</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">TABLE OF CONTENTS</A>&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="width: 42%; border-bottom: Black 1pt solid; text-align: center"><B>Title of Securities to be Registered</B></TD>
      <TD STYLE="width: 14%; border-bottom: Black 1pt solid; text-align: center"><B>Amount to be Registered<SUP>(1)</SUP></B></TD>
      <TD STYLE="width: 14%; border-bottom: Black 1pt solid; text-align: center"><B>Proposed Maximum Offering Price Per Share<SUP>(2)</SUP></B></TD>
      <TD STYLE="width: 18%; border-bottom: Black 1pt solid; text-align: center"><B>Proposed Maximum Aggregate Offering Price<SUP>(2)</SUP></B></TD>
      <TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: center"><B>Amount of<BR>
  Registration Fee</B></TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid">Common Stock, par value $0.001 per share</TD>
      <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">7,753,484<SUP>(3)</SUP></TD>
      <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">$10.36</TD>
      <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">$80,326,094.24</TD>
      <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">$7,446.23</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
  this Registration Statement also covers such additional shares of common stock, par value $0.001 per share (&ldquo;Common Stock&rdquo;),
  of PLx Pharma Inc., a Delaware corporation (the &ldquo;Company&rdquo;), that become issuable under the plans listed in footnote 3 below
  by reason of any stock split, stock dividend, recapitalization or other similar transaction that results in an increase in the number
  of outstanding shares of Common Stock.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Estimated solely for the purposes of calculating the registration fee pursuant to Rules 457(c) and 457(h)
  under the Securities Act, based on the average of the high and low prices of the Common Stock as reported on the Nasdaq Global Market
  on November 19, 2021.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Represents 7,000,000 shares of Common Stock issuable pursuant to the PLx Pharma Inc. 2018 Incentive Plan
  (as amended, the &ldquo;2018 Plan&rdquo;), and 753,484 shares of Common Stock issuable pursuant to the PLx Pharma Inc. 2015 Omnibus Incentive
  Plan (as amended, the &ldquo;2015 Plan&rdquo;).</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 3 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">TABLE OF CONTENTS</A>&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">EXPLANATORY NOTE</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has prepared this
  Registration Statement in accordance with the requirements of Form S-8 under the Securities Act, to register 7,753,484 shares of Common
  Stock issuable or issued pursuant to the 2015 Plan and the 2018 Plan.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Form S-8 includes a Reoffer
  Prospectus prepared in accordance with Part I of Form S-3 under the Securities Act. The Reoffer Prospectus may be utilized for reofferings
  and resales of shares of Common Stock acquired pursuant to the 2015 Plan and the 2018 Plan.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B>PART I</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B>INFORMATION REQUIRED IN
  THE SECTION 10(a) PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The information required
  by Item 1 and Item 2 of Part I of Form S-8 is omitted from this filing in accordance with Rule 428 under the Securities Act and the introductory
  note to Part I of Form S-8.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The documents containing the information in Part I
  relating to the Plans will be sent or given to participants in the Plans as specified by Rule 428(b)(1) promulgated under the Securities
  Act. In accordance with the instructions to Part I of Form S-8, such documents will not be filed with the SEC either as part of this Registration
  Statement or as prospectuses or prospectus supplements pursuant to Rule 424 promulgated under the Securities Act. These documents and
  the documents incorporated by reference pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute the prospectus
  (the &ldquo;Section 10(a) Prospectus&rdquo;) as required by Section 10(a) of the Securities Act in respect of future issuances under the
  Plans.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Upon written or oral request, any of the documents
  incorporated by reference in Item 3 of Part II of this Registration Statement, which are also incorporated by reference in the Section
  10(a) Prospectus, other documents required to be delivered to eligible participants pursuant to Rule 428(b), or additional information
  about the Plans, will be available without charge by contacting the Corporate Secretary at 9 Fishers Lane, Ste. E, Sparta, New Jersey
  07871 or (973) 409-6541.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"></P>
  
  <!-- Field: Page; Sequence: 4 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">TABLE OF CONTENTS</A>&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B>7,753,484 Shares<BR>
  PLX PHARMA INC.<BR>
  Common Stock ($0.001 par value)</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">This prospectus relates to
  the reoffer and resale by certain selling stockholders of shares of PLx Pharma Inc. (&ldquo;PLx Pharma&rdquo;, the &ldquo;Company&rdquo;,
   &ldquo;we&rdquo;, &ldquo;our&rdquo; or &ldquo;us&rdquo;) or shares that may be issued by us to the selling stockholders upon the exercise
  of stock options granted under our 2015 Omnibus Incentive Plan (as amended, the &ldquo;2015 Plan&rdquo;) and our 2018 Stock Incentive
  Plan (as amended, the &ldquo;2018 Plan&rdquo;). This prospectus also relates to certain underlying options, shares of restricted stock
  and shares relating to restricted stock units that have not as of this date been granted or issued. If and when such options, shares of
  restricted stock, or shares relating to restricted stock units are granted to persons required to use the prospectus to reoffer and resell
  the shares underlying such options, the shares of restricted stock or the shares relating to the restricted stock units, we will distribute
  a prospectus supplement. The shares are being reoffered and resold for the account of the selling stockholders and we will not receive
  any of the proceeds from the resale of the shares.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">The selling stockholders have
  advised us that the resale of their shares may be effected from time to time in one or more transactions on the Nasdaq Global Market,
  in negotiated transactions or otherwise, at market prices prevailing at the time of the sale or at prices otherwise negotiated. See &ldquo;Plan
  of Distribution.&rdquo; We will bear all expenses in connection with the preparation of this prospectus. We will, however, receive the
  exercise price of any options, exercisable into shares that will be reoffered and resold, at the time of their exercise.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">Our common stock (&ldquo;Common
  Stock&rdquo;) is listed on the Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;PLXP&rdquo;. On November 19, 2021,
  the last reported sale price of our Common Stock on Nasdaq was $10.07.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><B><I>Investing in our Common
  Stock involves a high degree of risk. You should carefully review the risks and uncertainties we have described under the section titled
   &ldquo;Risk Factors&rdquo; on page 1 of this prospectus, and under similar sections in the other documents that are incorporated
  by reference into this prospectus, including those filed after the date hereof.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><B>NEITHER THE SECURITIES
  AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS
  IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The date of this prospectus is November 22, 2021.&nbsp;</B></P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 5 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">TABLE OF CONTENTS</A>&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><A NAME="TableOfContents"></A>TABLE OF CONTENTS</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 89%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><A HREF="#ABOUTTHISPROSPECTUS">ABOUT THIS PROSPECTUS</A></TD>
      <TD STYLE="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><A HREF="#ABOUTTHISPROSPECTUS">i</A></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><A HREF="#PROSPECTUSSUMMARY">PROSPECTUS SUMMARY</A></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><A HREF="#PROSPECTUSSUMMARY">ii</A></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><A HREF="#RISKFACTORS">RISK FACTORS</A></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><A HREF="#RISKFACTORS">1</A></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><A HREF="#FORWARD-LOOKINGSTATEMENTS">FORWARD-LOOKING STATEMENTS</A></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><A HREF="#FORWARD-LOOKINGSTATEMENTS">1</A></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><A HREF="#USEOFPROCEEDS">USE OF PROCEEDS</A></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><A HREF="#USEOFPROCEEDS">1</A></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><A HREF="#DETERMINATIONOFOFFERINGPRICE">DETERMINATION OF OFFERING PRICE</A></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><A HREF="#DETERMINATIONOFOFFERINGPRICE">1</A></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><A HREF="#SELLINGSTOCKHOLDERS">SELLING STOCKHOLDERS</A></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><A HREF="#SELLINGSTOCKHOLDERS">1</A></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><A HREF="#PLANOFDISTRIBUTION">PLAN OF DISTRIBUTION</A></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><A HREF="#PLANOFDISTRIBUTION">3</A></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><A HREF="#LEGALMATTERS">LEGAL MATTERS</A></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><A HREF="#LEGALMATTERS">5</A></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><A HREF="#ADDITIONALINFORMATION">ADDITIONAL INFORMATION</A></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><A HREF="#ADDITIONALINFORMATION">5</A></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><A HREF="#INCORPORATIONOFCERTAININFORMATIONBYREFERENCE">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><A HREF="#INCORPORATIONOFCERTAININFORMATIONBYREFERENCE">5</A></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><A HREF="#DISCLOSUREOFCOMMISSIONPOSITIONONINDEMNIFICATIONFORSECURITIESACTLIABILITIES">DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</A></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><A HREF="#DISCLOSUREOFCOMMISSIONPOSITIONONINDEMNIFICATIONFORSECURITIESACTLIABILITIES">6</A></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><A HREF="#PARTII">PART II&nbsp;&nbsp;INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</A></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><A HREF="#PARTII">7</A></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><A HREF="#SIGNATURES">SIGNATURES</A></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><A HREF="#SIGNATURES">11</A></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><A HREF="#POWEROFATTORNEY">POWER OF ATTORNEY</A></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><A HREF="#POWEROFATTORNEY">11</A></TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 6 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">TABLE OF CONTENTS</A>&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="ABOUTTHISPROSPECTUS"></A><FONT STYLE="text-transform: none">ABOUT
  THIS PROSPECTUS</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">This prospectus is part of a registration statement
  on Form S-8 that we filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;). All references to &ldquo;Company,&rdquo; &ldquo;we,&rdquo;
   &ldquo;our&rdquo; or &ldquo;us&rdquo; refer solely to PLx Pharma Inc. and not to the persons who manage us or sit on our Board of Directors
  or are our stockholders. Reference to &ldquo;selling stockholders&rdquo; refers to those stockholders listed herein in the section titled
   &ldquo;Selling Stockholders&rdquo; beginning on page 1 of this prospectus, who may sell shares from time to time as described
  in this prospectus. All trade names used in this prospectus are either our registered trademarks or trademarks of their respective holders.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">No person has been authorized to give any information
  or to make any representations other than those contained in this prospectus, and if given or made, such information or representations
  must not be relied upon as having been authorized by the Company, any selling stockholder or by any other person. Neither the delivery
  of this prospectus nor any sale made hereunder shall, under any circumstances, create any implication that information herein is correct
  as of any time subsequent to the date hereof. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy
  any security other than the securities covered by this prospectus, nor does it constitute an offer to or solicitation of any person in
  any jurisdiction in which such offer or solicitation may not lawfully be made.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">This document may only be used where it is legal
  to sell these securities. The information contained in this prospectus (and in any supplement or amendment to this prospectus) is accurate
  only as of the date on the front of the document, and any information we have incorporated by reference is accurate only as of the date
  of the document incorporated by reference, regardless of the time of delivery of this prospectus or any sale of our Common Stock. Our
  business, financial condition, results of operations and prospects may have changed since those dates.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We urge you to read carefully this prospectus
  (as supplemented and amended), together with the information incorporated herein by reference as described in the section titled &ldquo;Incorporation
  of Certain Information by Reference&rdquo; before deciding whether to invest in any of the Common Stock being offered.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">This prospectus incorporates by reference market
  data, industry statistics and other data that have been obtained from, or compiled from, information made available by third parties.
  We have not independently verified their data.</P>
  
  <!-- Field: Page; Sequence: 7; Options: NewSection -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">TABLE OF CONTENTS</A>&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="PROSPECTUSSUMMARY"></A><FONT STYLE="text-transform: none">PROSPECTUS
  SUMMARY</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>This summary highlights selected information
  contained elsewhere or incorporated by reference in this prospectus. This summary may not contain all the information that you should
  consider before determining whether to invest in our securities. You should read the entire prospectus carefully, including the information
  included in the &ldquo;Risk Factors&rdquo; section, as well as our consolidated financial statements, notes to the consolidated financial
  statements and the other information incorporated by reference into this prospectus, as well as the exhibits to the registration statement
  of which this prospectus is a part, before making an investment decision.</I></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>The Company</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">We are a commercial-stage
  drug delivery platform technology company focused on improving how and where active pharmaceutical ingredients (APIs) are absorbed in
  the gastrointestinal (GI) tract via its clinically validated and patent protected PLxGuard&trade; technology. We believe this platform
  has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach
  injury associated with certain drugs.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">VAZALORE&trade; 325 mg and
  VAZALORE&trade; 81 mg (referred to together as &ldquo;VAZALORE&rdquo;) are FDA-approved liquid-filled aspirin capsule, available in 81
  mg and 325 mg doses. VAZALORE delivers aspirin differently from plain and enteric coated aspirin products. The special complex inside
  the capsule allows for targeted release of aspirin, limiting its direct contact with the stomach. VAZALORE delivers fast, reliable absorption
  for pain relief plus the lifesaving benefits of aspirin.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">Our commercialization strategy
  targets the over-the-counter (&ldquo;OTC&rdquo;) market, taking advantage of the existing distribution channels for aspirin. We market
  VAZALORE to the healthcare professional and the consumer through several sales and marketing channels. Our product pipeline also includes
  other oral NSAIDs using the PLxGuard drug delivery platform that may be developed, including PL1200 Ibuprofen 200 mg and PL1200 Ibuprofen
  400 mg, for pain and inflammation in Phase I clinical stage.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">We were originally incorporated
  in Texas in 2002 and re-incorporated in Delaware in 2015. On April 19, 2017, Dipexium Acquisition Corp., a Delaware corporation (&ldquo;Merger
  Sub&rdquo;) and a wholly-owned subsidiary of Dipexium Pharmaceuticals, Inc., a Delaware corporation (&ldquo;Dipexium&rdquo;), merged with
  and into PLx Pharma Inc., a privately-held Delaware corporation (&ldquo;Old PLx&rdquo;), pursuant to the terms of that certain Agreement
  and Plan of Merger and Reorganization dated as of December 22, 2016 by and among Dipexium, Merger Sub and Old PLx (the &ldquo;Merger&rdquo;).
  As part of the Merger, Dipexium was re-named PLx Pharma Inc. and Old PLx was re-named PLx Opco Inc. Following completion of the Merger,
  Old PLx became a wholly-owned subsidiary of the Company. Since the completion of the Merger, the business we have conducted has been primarily
  the business of Old PLx. The combined company, renamed as PLx Pharma Inc., together with its subsidiary PLx Opco Inc., is referred to
  herein as the &ldquo;Company.&rdquo;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">The Company&rsquo;s headquarters
  is located at 9 Fishers Lane, Ste. E, Sparta, New Jersey 07871. Our telephone number is (973) 409-6541.&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in"></P>
  
  <!-- Field: Page; Sequence: 8 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">TABLE OF CONTENTS</A>&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="RISKFACTORS"></A><FONT STYLE="text-transform: none">RISK
  FACTORS</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Investing in our securities involves significant
  risks. Before deciding whether to invest in our securities, you should carefully consider the risks, uncertainties and assumptions described
  in this prospectus and any accompanying prospectus supplement, including the risk factors set forth in our filings with the SEC that are
  incorporated by reference herein and therein, including the risk factors in our most recent Annual Report on Form 10-K, as amended, as
  revised or supplemented by our Quarterly Reports on Form 10-Q, and which may be amended, supplemented or superseded from time to time
  by other reports we file with the SEC in the future. There may be other unknown or unpredictable economic, business, competitive, regulatory
  or other factors that could have material adverse effects on our future results. If any of these risks actually occurs, our business,
  business prospects, financial condition or results of operations could be seriously harmed. Please also read carefully the section below
  titled &ldquo;Forward-Looking Statements.&rdquo;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="FORWARD-LOOKINGSTATEMENTS"></A><FONT STYLE="text-transform: none">FORWARD-LOOKING
  STATEMENTS</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">This prospectus and certain documents incorporated
  by reference in this prospectus contain forward-looking statements. In some cases, you can identify forward-looking statements by terms
  such as &ldquo;may,&rdquo; &ldquo;intend,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo;
   &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential,&rdquo; or the negative of
  these terms, and similar expressions. These statements reflect our current views with respect to future events. These statements involve
  known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially
  different from any future results, performances or achievements expressed or implied by the forward-looking statements, many of which
  are discussed in greater detail in the section titled &ldquo;Risk Factors&rdquo; in this prospectus.</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="USEOFPROCEEDS"></A><FONT STYLE="text-transform: none">USE
  OF PROCEEDS</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The shares of Common Stock offered hereby are
  being registered for the account of the selling stockholders identified in this prospectus. The selling stockholders will receive all
  of the net proceeds from sales of the Common Stock pursuant to this prospectus. We will not receive any part of the proceeds from such
  sales of Common Stock. We will, however, receive the exercise price of the options at the time of their exercise. We expect to use any
  such proceeds primarily for working capital and general corporate purposes.</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="DETERMINATIONOFOFFERINGPRICE"></A><FONT STYLE="text-transform: none">DETERMINATION
  OF OFFERING PRICE</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The selling stockholders may sell the shares
  of our Common Stock issued to them from time to time at prices and at terms prevailing or at prices related to the current market price,
  or in negotiated transactions.</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="SELLINGSTOCKHOLDERS"></A><FONT STYLE="text-transform: none">SELLING
  STOCKHOLDERS</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">This reoffer prospectus relates to the reoffer
  and resale of shares of Common Stock that have been issued or that may be issued in the future to the selling stockholders, listed below,
  or future selling stockholders under our 2015 Plan and 2018 Plan. Certain unnamed non-affiliates, each of whom may sell up to the lesser
  of 1,000 shares of Common Stock or 1% of the shares of our Common Stock issuable under the Plans may use this reoffer prospectus for reoffers
  and resales.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The following table sets forth (i) the number
  of shares of Common Stock beneficially owned by each selling stockholder at November 16, 2021, (ii) the number of shares to be offered
  for resale by each selling stockholder (i.e., the total number of shares underlying options held by each selling stockholder irrespective
  of whether such options are presently exercisable or exercisable within sixty days of November 16, 2021), and (iii) the number and percentage
  of shares of our Common Stock to be held by each selling stockholder after completion of the offering (i.e., such number is exclusive
  of shares underlying options that have not been exercised). Except as otherwise set forth below, the address of the persons listed below
  is c/o PLx Pharma Inc., 9 Fishers Lane, Suite E, Sparta, New Jersey 07871 and each of the persons listed has, to our knowledge, sole voting
  and investment power with respect to the indicated shares of Common Stock.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 9; Options: NewSection -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">TABLE OF CONTENTS</A>&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">All information with respect to the Common Stock ownership
  of the selling stockholders has been furnished by or on behalf of the selling stockholders. We believe, based on information supplied
  by the selling stockholders, that except as may otherwise be indicated in the footnotes to the table below, the selling stockholders have
  sole voting and dispositive power with respect to the Common Stock reported as beneficially owned by them. Because the selling stockholders
  identified in the table may sell some or all of the Common Stock owned by them and covered by this reoffer prospectus, and because there
  are currently no agreements, arrangements or understandings with respect to the sale of any of the Common Stock, no estimate can be given
  as to the number of Common Stock available for resale hereby that will be held by the selling stockholders upon termination of this offering.
  In addition, the selling stockholders may have sold, transferred or otherwise disposed of, or may sell, transfer or otherwise dispose
  of, at any time and from time to time, the common shares they hold in transactions exempt from the registration requirements of the Securities
  Act after the date on which they provided the information set forth in the table below. We have, therefore, assumed for the purposes of
  the following table, that the selling stockholders will sell all of the common shares owned beneficially by them that are covered by this
  reoffer prospectus, but will not sell any other common shares that they presently own.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="font-weight: bold; text-align: center">Name</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
      <TD STYLE="font-weight: bold; text-align: center">Relationship to the Company</TD><TD>&nbsp;</TD>
      <TD COLSPAN="3" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Number of shares of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Common Stock</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Beneficially Owned at</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>November 16, 2021 (1)</B></P></TD><TD>&nbsp;</TD>
      <TD COLSPAN="3" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Number of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Shares to be</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Offered for</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Resale (2)</B></P></TD><TD>&nbsp;</TD>
      <TD COLSPAN="3" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Number of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>shares of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Common Stock Beneficially Owned</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>After</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Completion of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>the Offering (3)</B></P></TD><TD>&nbsp;</TD>
      <TD COLSPAN="3" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Percentage of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Class to be</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Owned After</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Completion</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Offering</B></P></TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 15%; text-align: left">Michael J. Valentino</TD><TD STYLE="width: 2%">&nbsp;</TD>
      <TD STYLE="width: 15%; text-align: left">Executive Chairman of the Board of Directors</TD><TD STYLE="width: 2%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">1,061,013</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">432,509</TD><TD STYLE="width: 1%; text-align: left">(4)</TD><TD STYLE="width: 2%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">815,171</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">2.9</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">Natasha Giordano</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">CEO and Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">620,655</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,240,127</TD><TD STYLE="text-align: left">(5)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,086</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: left">Rita M. O&rsquo;Connor</TD><TD>&nbsp;</TD>
      <TD>CFO</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">242,420</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">544,675</TD><TD STYLE="text-align: left">(6)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,970</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">Gary S. Balkema</TD><TD>&nbsp;</TD>
      <TD>Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,779</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89,001</TD><TD STYLE="text-align: left">(7)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,445</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: left">Anthony Bartsh</TD><TD>&nbsp;</TD>
      <TD>Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">Kirk Calhoun</TD><TD>&nbsp;</TD>
      <TD>Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,009</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89,001</TD><TD STYLE="text-align: left">(8)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,675</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: left">Robert Casale</TD><TD>&nbsp;</TD>
      <TD>Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,044</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89,001</TD><TD STYLE="text-align: left">(9)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,710</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="text-align: left">John W. Hadden II</TD><TD>&nbsp;</TD>
      <TD>Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,024</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89,001</TD><TD STYLE="text-align: left">(10)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,690</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    </TABLE>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">____________</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">*</TD>
      <TD STYLE="padding-bottom: 12pt">Less than one percent</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>(1)</TD>
      <TD STYLE="padding-bottom: 12pt">A person is deemed to be the beneficial owner of voting securities that can be acquired by such person within 60 days after November 16, 2021 upon the exercise of options, warrants or convertible securities.&nbsp;&nbsp;Each beneficial owner&rsquo;s percentage ownership is determined by assuming that options, warrants or convertible securities that are held by such person (but not those held by any other person) and that are currently exercisable (i.e., that are exercisable within 60 days from November 16, 2021) have been exercised.&nbsp;&nbsp;Unless otherwise noted, we believe that all persons named in the table have sole voting and investment power with respect to all shares beneficially owned by them.</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD></TD></TR></TABLE>
  
  <!-- Field: Page; Sequence: 10 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">TABLE OF CONTENTS</A>&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 48px">(2)</TD>
      <TD STYLE="padding-bottom: 12pt">Includes vested and non-vested stock options.</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>(3)</TD>
      <TD STYLE="padding-bottom: 12pt">Includes the aggregate ownership of the Company&rsquo;s Common Stock assuming all of the shares of Common Stock offered for resale pursuant to their offering have been sold.</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>(4)</TD>
      <TD STYLE="padding-bottom: 12pt">Includes shares underlying 245,842 stock options that will vest within 60 days of November 16, 2021, as well as shares underlying 186,667 stock options will vest more than 60 days after November 16, 2021 held by Mr. Valentino.</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>(5)</TD>
      <TD STYLE="padding-bottom: 12pt">Includes shares underlying 619,569 stock options that will vest within 60 days of November 16, 2021, as well as shares underlying 620,558 stock options that will vest more than 60 days after November 16, 2021 held by Ms. Giordano.</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>(6)</TD>
      <TD STYLE="padding-bottom: 12pt">Includes shares underlying 229,450 stock options that will vest within 60 days of November 16, 2021, as well as shares underlying 315,225 stock options that will vest more than 60 days after November 16, 2021 held by Ms. O&rsquo;Connor.</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>(7)</TD>
      <TD STYLE="padding-bottom: 12pt">Includes shares underlying 42,334 stock options that will vest within 60 days of November 16, 2021, as well as shares underlying 46,667 stock options that will vest more than 60 days after November 16, 2021 held by Mr. Balkema.</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>(8)</TD>
      <TD STYLE="padding-bottom: 12pt">Includes shares underlying 42,334 stock options that will vest within 60 days of November 16, 2021, as well as shares underlying 46,667 stock options that will vest more than 60 days after November 16, 2021 held by Mr. Calhoun.</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>(9)</TD>
      <TD STYLE="padding-bottom: 12pt">Includes shares underlying 42,334 stock options that will vest within 60 days of November 16, 2021, as well as shares underlying 46,667 stock options that will vest more than 60 days after November 16, 2021 held by Mr. Casale.</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>(10)</TD>
      <TD STYLE="padding-bottom: 12pt">Includes shares underlying 42,334 stock options that will vest within 60 days of November 16, 2021, as well as shares underlying 46,667 stock options that will vest more than 60 days after November 16, 2021 held by Mr. Hadden.</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="PLANOFDISTRIBUTION"></A><FONT STYLE="text-transform: none">PLAN
  OF DISTRIBUTION</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The selling stockholders, which as used herein
  includes donees, pledgees, transferees or other successors-in-interest, selling shares of Common Stock may, from time to time, sell, transfer
  or otherwise dispose of any or all of their shares of Common Stock or interests in shares of Common Stock on any stock exchange, market
  or trading facility on which the shares are traded or in private transactions. The selling stockholders may sell their shares of our common
  stock pursuant to this prospectus at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing
  market price, at varying prices determined at the time of sale, or at negotiated prices.</P>
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The
  selling stockholders may use any one or more of the following methods when disposing of shares or interests therein:</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block
  as principal to facilitate the transaction;</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</TD></TR></TABLE>
  
  
  <!-- Field: Page; Sequence: 11 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">TABLE OF CONTENTS</A>&nbsp;</P></DIV>
      <!-- Field: /Page -->
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>an exchange distribution in accordance with the rules of the applicable exchange;</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>privately negotiated transactions;</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>short sales;</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>a combination of any such methods of sale; and</TD></TR></TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>any other method permitted pursuant to applicable law.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The selling stockholders may effect such transactions
  by selling shares to or through broker-dealers, and all such broker-dealers may receive compensation in the form of discounts, concessions,
  or commissions from the selling stockholders and/or the purchasers of shares of Common Stock for whom such broker-dealers may act as agents
  or to whom they sell as principals, or both (which compensation as to a particular broker-dealer might be in excess of customary commissions).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Any broker-dealer acquiring Common Stock from
  the selling stockholders may sell the shares either directly, in its normal market-making activities, through or to other brokers on
  a principal or agency basis or to its customers. Any such sales may be at prices then prevailing on Nasdaq or at prices related to such
  prevailing market prices or at negotiated prices to its customers or a combination of such methods. The selling stockholders and any
  broker-dealers that act in connection with the sale of the Common Stock hereunder might be deemed to be &ldquo;underwriters&rdquo; within
  the meaning of Section 2(11) of the Securities Act; any commissions received by them and any profit on the resale of shares as principal
  might be deemed to be underwriting discounts and commissions under the Securities Act. Any such commissions, as well as other expenses
  incurred by the selling stockholders and applicable transfer taxes, are payable by the selling stockholders.</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The selling stockholders reserve the right to
  accept, and together with any agent of the selling stockholder, to reject in whole or in part any proposed purchase of the shares of Common
  Stock. The selling stockholders will pay any sales commissions or other seller&rsquo;s compensation applicable to such transactions.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We have not registered or qualified offers and
  sales of shares of the Common Stock under the laws of any country, other than the United States. To comply with certain states&rsquo;
  securities laws, if applicable, the selling stockholders will offer and sell their shares of Common Stock in such jurisdictions only through
  registered or licensed brokers or dealers. In addition, in certain states the selling stockholders may not offer or sell shares of Common
  Stock unless we have registered or qualified such shares for sale in such states or we have complied with an available exemption from
  registration or qualification.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The selling stockholders have represented to
  us that any purchase or sale of shares of Common Stock by them will comply with Regulation M promulgated under the Securities Exchange
  Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). In general, Rule 102 under Regulation M prohibits any person connected with
  a distribution of our Common Stock (a &ldquo;Distribution&rdquo;) from directly or indirectly bidding for, or purchasing for any account
  in which he or she has a beneficial interest, any of our Common Stock or any right to purchase our Common Stock, for a period of one
  business day before and after completion of his or her participation in the distribution (we refer to that time period as the &ldquo;Distribution
  Period&rdquo;).</P>
  
  <!-- Field: Page; Sequence: 12 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">TABLE OF CONTENTS</A>&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">During the Distribution Period, Rule 104 under
  Regulation M prohibits the selling stockholders and any other persons engaged in the Distribution from engaging in any stabilizing bid
  or purchasing our Common Stock except for the purpose of preventing or retarding a decline in the open market price of our Common Stock.
  No such person may effect any stabilizing transaction to facilitate any offering at the market. Inasmuch as the selling stockholders
  will be reoffering and reselling our Common Stock at the market, Rule 104 prohibits them from effecting any stabilizing transaction in
  contravention of Rule 104 with respect to our Common Stock.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">There can be no assurance that the selling stockholders
  will sell any or all of the shares offered by them hereunder or otherwise.</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="LEGALMATTERS"></A><FONT STYLE="text-transform: none">LEGAL
  MATTERS</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Certain legal matters in connection with the
  issuance of the shares of Common Stock offered hereby have been passed upon for us by Olshan Frome Wolosky LLP, New York, New York.</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="ADDITIONALINFORMATION"></A><FONT STYLE="text-transform: none">ADDITIONAL
  INFORMATION</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We have filed with the SEC a Registration Statement
  on Form S-8 under the Securities Act with respect to the shares offered hereby. We file annual, quarterly and current reports, proxy statements
  and other information with the SEC. The SEC maintains an Internet site at http://www.sec.gov/ that contains reports, proxy and information
  statements, and other information regarding issuers, such as us, that file electronically with the SEC. Additionally, you may access our
  filings with the SEC through our website at https://plxpharma.com/. The information on our website is not part of this prospectus.</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="INCORPORATIONOFCERTAININFORMATIONBYREFERENCE"></A><FONT STYLE="text-transform: none">INCORPORATION
  OF CERTAIN INFORMATION BY REFERENCE</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The SEC allows us to incorporate by reference
  the information we file with it, which means that we can disclose important information to you by referring you to those documents. The
  information we incorporate by reference is considered to be part of this prospectus, and information that we file later with the SEC will
  automatically update and supersede this information. We incorporate by reference the documents listed below and any future filings made
  by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, until the sale of all the shares of common stock that
  are part of this offering. The documents we are incorporating by reference are as follows:</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2020 filed with the SEC on March 12, 2021, as amended
  by the Form 10-K/A filed with the SEC on April 30, 2021;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Quarterly Reports on Form 10-Q the Company for the fiscal quarter ended March 31, 2021, filed with the SEC on May 14, 2021; for the
  fiscal quarter ended June 30, 2021, filed with the SEC on August 6, 2021; and for the fiscal quarter ended September 30, 2021, filed with
  the SEC on November 12, 2021;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; background-color: white">&nbsp;&nbsp;</P>
  
  <!-- Field: Page; Sequence: 13 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">TABLE OF CONTENTS</A>&nbsp;</P></DIV>
      <!-- Field: /Page -->
  <P STYLE="margin-top: 0; margin-bottom: 0"></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Current Reports on Form 8-K of the Company filed with the SEC on January 11, 2021, March 1, 2021 (other than information furnished
  rather than filed), March 2, 2021, March 3, 2021, March 12, 2021 (other than information furnished rather than filed), March 17, 2021,
  May 14, 2021 (other than information furnished rather than filed), August 6, 2021 (other than information furnished rather than filed),
  August 6, 2021, September 21, 2021 (other than information furnished rather than filed) and November 12, 2021 (other than information
  furnished rather than filed); and</TD></TR></TABLE>
  <P STYLE="margin-top: 0; margin-bottom: 0"></P>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>The description of the Common Stock contained in the Company&rsquo;s Registration Statement on Form 8-A, declared effective by the
  SEC on March 12, 2014, including any amendments or reports filed for the purpose of updating such description.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">All documents filed pursuant
  to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of the initial registration statement and prior to effectiveness
  of the registration statement and after the date of this prospectus but prior to the filing of a post-effective amendment which indicates
  that all securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated
  by reference into this Registration Statement and to be a part hereof from the date of filing of such documents, provided, however, that
  the registrant is not incorporating any information furnished under either Item 2.02 or Item 7.01 of any Current Report on Form 8-K.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Any document, and any statement
  contained in a document, incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for
  purposes of this prospectus to the extent that a statement contained herein, or in any other subsequently filed document that also is
  incorporated or deemed to be incorporated by reference herein, modifies or supersedes such document or statement. Any such document or
  statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The documents incorporated
  by reference in this prospectus may be obtained from us without charge and will be provided to each person, including any beneficial owner,
  to whom a prospectus is delivered. You may obtain a copy of the documents at no cost by submitting an oral or written request to:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PLx Pharma Inc.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">9 Fishers Lane, Ste. E</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Sparta, New Jersey 07871</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Attn: Corporate Secretary</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(973) 409-6541</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Additional information
  about us is available at our web site located at https://plxpharma.com/. Information contained in our web site is not a part of this prospectus.</P>
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="DISCLOSUREOFCOMMISSIONPOSITIONONINDEMNIFICATIONFORSECURITIESACTLIABILITIES"></A><FONT STYLE="text-transform: none">DISCLOSURE
  OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Insofar as indemnification
  for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Company, the Company
  has been advised that it is the SEC&rsquo;s opinion that such indemnification is against public policy as expressed in the Securities
  Act and is, therefore, unenforceable.</P>
  
  <!-- Field: Page; Sequence: 14 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">TABLE OF CONTENTS</A>&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="PARTII"></A><FONT STYLE="text-transform: none"><B>PART
  II<BR>
  <BR>
  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B></FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 3.</B></TD><TD STYLE="text-align: justify"><B>Incorporation of Documents by Reference</B></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">The following documents previously
  filed by the Company with the SEC under the Securities Act and the Exchange Act, are incorporated herein by reference (other than any
  such documents or portions thereof that are furnished under Item 2.02 or Item 7.01 of Form 8-K, unless otherwise indicated therein, including
  any exhibits included with such Items):</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2020 filed with the SEC on March 12, 2021, as amended
  by the Form 10-K/A filed with the SEC on April 30, 2021;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Quarterly Report on Form 10-Q the Company for the fiscal quarter ended March 31, 2021, filed with the SEC on May 14, 2021; for the
  fiscal quarter ended June 30, 2021, filed with the SEC on August 6, 2021; and for the fiscal quarter ended September 30, 2021, filed with
  the SEC on November 12, 2021;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Current Reports on Form 8-K of the Company filed with the SEC on January 11, 2021, March 1, 2021 (other than information furnished
  rather than filed), March 2, 2021, March 3, 2021, March 12, 2021 (other than information furnished rather than filed) and March 17, 2021,
  May 14, 2021 (other than information furnished rather than filed), August 6, 2021 (other than information furnished rather than filed),
  August 6, 2021, September 21, 2021 (other than information furnished rather than filed) and November 12, 2021 (other than information
  furnished rather than filed); and</TD></TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in"></P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>The description of the Common Stock contained in the Company&rsquo;s Registration Statement on Form 8-A, declared effective by the
  SEC on March 12, 2014, including any amendments or reports filed for the purpose of updating such description.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">All documents filed by the
  Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this Registration Statement (other
  than any such documents or portions thereof that are furnished under Item 2.02 or Item 7.01 of Form 8-K, unless otherwise indicated therein,
  including any exhibits included with such Items), prior to the filing of a post-effective amendment to this Registration Statement which
  indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed
  to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">Any statement contained in
  this Registration Statement or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified
  or superseded for purposes of this Registration Statement to the extent that a statement contained or incorporated by reference herein
  or in any subsequently filed document that is deemed to be incorporated by reference herein modifies or supersedes such statement. Any
  such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration
  Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 4.</B></TD><TD STYLE="text-align: justify"><B>Description of Securities</B></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 5.</B></TD><TD STYLE="text-align: justify"><B>Interests of Named Experts and Counsel</B></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">No expert or counsel named in this Registration Statement
  as having prepared or certified any part of this Registration Statement or having given an opinion upon the validity of the securities
  being registered or upon other legal matters in connection with the registration or offering of the common stock was employed on a contingency
  basis or had, or is to receive, in connection with the offering, a substantial interest, directly or indirectly, in the registrant or
  any of its parents or subsidiaries.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 15 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">TABLE OF CONTENTS</A>&nbsp;</P></DIV>
      <!-- Field: /Page -->
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 6.</B></TD><TD><B>Indemnification of Directors and Officers</B></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The Company
  may, to the fullest extent permitted by Section 145 of the Delaware General Corporation Law (&ldquo;DGCL&rdquo;), as the same may be amended
  and supplemented, indemnify any and all persons whom it shall have power to indemnify under said section from and against any and all
  of the expenses, liabilities, costs, fees or other matters referred to in or covered by said section, and the indemnification provided
  for shall not be deemed exclusive of any other rights to which a person indemnified may be entitled under any bylaw, agreement, insurance,
  vote of stockholders or disinterested directors or otherwise, both as to action in his official capacity and as to action in another capacity
  while holding such office, and shall continue as to a person who has ceased to be director, officer, employee or agent and shall inure
  to the benefit of the heirs, executors and administrators of such a person.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">No director
  shall be personally liable to the Company or our stockholders for monetary damages for any breach of fiduciary duty by such director as
  a director. Notwithstanding the foregoing sentence, a director shall be liable to the extent provided by applicable law: (i) for breach
  of the director&rsquo;s duty of loyalty to the Company or our stockholders, (ii) for acts or omissions not in good faith or which involve
  intentional misconduct or a knowing violation of law, (iii) pursuant to Section 174 of the DGCL or (iv) for any transaction from which
  the director derived an improper personal benefit.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The Company
  is subject to Section 203 of the DGCL, which prevents an &ldquo;interested stockholder&rdquo; (defined in Section 203, generally, as a
  person owning 15% or more of a corporation&rsquo;s outstanding voting stock) from engaging in a &ldquo;business combination&rdquo; with
  a publicly-held Delaware corporation for three (3) years following the date such person became an interested stockholder, unless: (i)
  before such person became an interested stockholder, the board of directors of the corporation approved the transaction in which the interested
  stockholder became an interested stockholder or approved the business combination; (ii) upon consummation of the transaction that resulted
  in the interested stockholder&rsquo;s becoming an interested stockholder, the interested stockholder owns at least 85% of the voting stock
  of the corporation outstanding at the time the transaction commenced (subject to certain exceptions); or (iii) following the transaction
  in which such person became an interested stockholder, the business combination is approved by the board of directors of the corporation
  and authorized at a meeting of stockholders by the affirmative vote of the holders of 66% of the outstanding voting stock of the corporation
  not owned by the interested stockholder. A &ldquo;business combination&rdquo; includes mergers, stock or asset sales and other transactions
  resulting in a financial benefit to the interested stockholder.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The provisions
  of Section 203 of the DGCL could have the effect of delaying, deferring or preventing a change in the control of the Company.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The Company
  maintains a directors and officers insurance and company reimbursement policy. The policy insures directors and officers against unindemnified
  loss arising from certain wrongful acts in their capacities and reimburses the Company for such loss for which the Company has lawfully
  indemnified the directors and officers. The policy contains various exclusions, none of which relate to the offering hereunder. The Company
  also has agreements with its directors and officers providing for the indemnification thereof under certain circumstances.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The foregoing
  summaries are qualified in their entirety by the terms and provisions of such arrangements.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 7.</B></TD><TD><B>Exemption From Registration Claimed</B></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">Not applicable.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; background-color: white"></P>
  
  <!-- Field: Page; Sequence: 16 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">TABLE OF CONTENTS</A>&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; background-color: white"><B>Item 8. Exhibits</B></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="width: 11%; padding-right: 5.75pt; padding-left: 5.75pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; border-bottom: Black 0.5pt solid"><B>Exhibit<BR>
      Number</B></P></TD>
      <TD STYLE="width: 89%; padding-right: 5.75pt; padding-left: 5.75pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; border-bottom: Black 0.5pt solid"><B>Exhibit Description</B></P></TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1497504/000143774917014488/ex3-3.htm" STYLE="-sec-extract: exhibit">4.1</A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1497504/000143774917014488/ex3-3.htm" STYLE="-sec-extract: exhibit">Amended and Restated Certificate of Incorporation of PLx Pharma Inc., incorporated herein by reference to Exhibit 3.3 to the Company&rsquo;s Quarterly Report on Form 10-Q, SEC File No. 001-36351, filed on August 11, 2017.</A></TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1497504/000092189519000545/ex31to8k11577002_02202019.htm">4.2</A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1497504/000092189519000545/ex31to8k11577002_02202019.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to the Amended Certificate of Incorporation of PLx Pharma Inc., incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K, SEC File No. 001-36351, filed on February 20, 2019.</A></TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1497504/000114420417003148/v456656_ex3-3.htm">4.3</A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1497504/000114420417003148/v456656_ex3-3.htm" STYLE="-sec-extract: exhibit">Amended and Restated Bylaws of PLx Pharma Inc., incorporated by reference to Exhibit 3.3 to the Company&rsquo;s Annual Report on Form 10-K, SEC File No. 001-36351, filed on January 20, 2017.</A></TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1497504/000114420417003660/v457129_s4.htm" STYLE="-sec-extract: exhibit">4.4</A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1497504/000114420417003660/v457129_s4.htm" STYLE="-sec-extract: exhibit">PLx Pharma Inc. 2015 Omnibus Incentive Plan, incorporated by reference to Annex G to the Company&rsquo;s Registration Statement on Form S-4, SEC File No. 333-215684, filed on January 25, 2017.</A></TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1497504/000092189520002477/def14a11577002_09252020.htm#AnnualReport" STYLE="-sec-extract: exhibit">4.5</A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1497504/000092189520002477/def14a11577002_09252020.htm#AnnualReport" STYLE="-sec-extract: exhibit">PLx Pharma Inc. 2018 Incentive Plan, incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Quarterly Report on Form 10-Q, SEC File No. 001-36351, filed on November 9, 2018.</A></TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1497504/000092189521002368/def14a11577002_10052021.htm" STYLE="-sec-extract: exhibit">4.6</A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1497504/000092189521002368/def14a11577002_10052021.htm" STYLE="-sec-extract: exhibit">PLx Pharma Inc. 2018 Incentive Plan, as amended, incorporated by reference to Annex A of the Company&rsquo;s Definitive Proxy Statement on Schedule 14A, SEC File No. 001-36351, filed on October 5, 2021.</A></TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><A HREF="ex51tos811577016_11192021.htm" STYLE="-sec-extract: exhibit">5.1</A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt"><A HREF="ex51tos811577016_11192021.htm" STYLE="-sec-extract: exhibit">Opinion of Olshan Frome Wolosky LLP.</A></TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><A HREF="ex231tos811577016_11192021.htm" STYLE="-sec-extract: exhibit">23.1</A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt"><A HREF="ex231tos811577016_11192021.htm" STYLE="-sec-extract: exhibit">Consent of Marcum LLP.</A></TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><A HREF="ex51tos811577016_11192021.htm" STYLE="-sec-extract: exhibit">23.2</A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt"><A HREF="ex51tos811577016_11192021.htm" STYLE="-sec-extract: exhibit">Consent of Olshan Frome Wolosky LLP (included in Exhibit 5.1).</A></TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: center"><A HREF="#POWEROFATTORNEY" STYLE="-sec-extract: exhibit">24.1</A></TD>
      <TD STYLE="vertical-align: bottom; padding-right: 5.75pt; padding-left: 5.75pt"><A HREF="#POWEROFATTORNEY" STYLE="-sec-extract: exhibit">Power of Attorney (included on the signature page hereto).</A></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"></P>
  
  <!-- Field: Page; Sequence: 17 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">TABLE OF CONTENTS</A>&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Item 9. Undertakings.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
  undersigned registrant hereby undertakes:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
  file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
  include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
  reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective
  amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration
  Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
  offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
  may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
  price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration
  Fee&rdquo; table in this effective Registration Statement; and</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
  include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any
  material change to such information in this Registration Statement;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0in"><I>provided, however</I>,
  that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those
  paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to section 13 or section 15(d) of the
  Exchange Act that are incorporated by reference in this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That,
  for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new
  registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
  be the initial bona fide offering thereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify; text-indent: 0in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
  remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
  of the offering.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
  undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the
  registrant&rsquo;s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee
  benefit plan&rsquo;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration
  Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
  at that time shall be deemed to be the initial bona fide offering thereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar
  as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
  the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such
  indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim
  for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer
  or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer
  or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the
  matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
  by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>
  
  <!-- Field: Page; Sequence: 18 -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><A HREF="#TableOfContents">TABLE OF CONTENTS</A>&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="SIGNATURES"></A><FONT STYLE="text-transform: none"><B>SIGNATURES</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Pursuant to the requirements of the Securities
  Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form
  S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City
  of Sparta, State of New Jersey on the 22nd day of November, 2021.</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">PLX PHARMA INC.</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">By:</TD>
      <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">/s/ Natasha Giordano</P></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 51%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="width: 6%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt">Name:</TD>
      <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt">Natasha Giordano</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Title:</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">President and Chief Executive Officer</TD></TR>
    </TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">
  <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="POWEROFATTORNEY"></A><FONT STYLE="text-transform: none"><B>POWER
  OF ATTORNEY</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">KNOW ALL MEN BY THESE PRESENTS, that each person
  whose signature appears below constitutes and appoints Natasha Giordano and Rita O&rsquo;Connor as his or her true and lawful attorney-in-fact,
  each acting alone, with full power of substitution and resubstitution for him or her and in his or her name, place and stead, in any and
  all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and to file the same,
  with exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and
  confirming all that said attorneys-in-fact or their substitutes, each acting alone, may lawfully do or cause to be done by virtue hereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Pursuant to the requirements of the Securities
  Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 39%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B><U>Signature</U></B></TD>
      <TD STYLE="width: 37%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B><U>Title</U></B></TD>
      <TD STYLE="width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B><U>Date</U></B></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>&nbsp;</B></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>&nbsp;</B></TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>&nbsp;</B></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">/s/ Natasha Giordano</P></TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">President, Chief Executive Officer and Director (Principal Executive Officer)</TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">November 22, 2021</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Natasha Giordano</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">/s/ Rita O&rsquo;Connor</P></TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Chief Financial Officer (Principal Financial and Accounting Officer)</TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">November 22, 2021</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Rita O&rsquo;Connor</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">/s/ Michael J. Valentino</P></TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Director and Executive Chairman of the Board</TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">November 22, 2021</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Michael J. Valentino</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">/s/ Gary Balkema</P></TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Director </TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">November 22, 2021</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Gary Balkema</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">/s/ Anthony Bartsh</P></TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Director </TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">November 22, 2021</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Anthony Bartsh</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">/s/ Robert Casale</P></TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Director</TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">November 22, 2021</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Robert Casale</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">/s/ Kirk Calhoun</P></TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Director</TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">November 22, 2021</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Kirk Calhoun</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">/s/ John W. Hadden II</P></TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Director</TD>
      <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">November 22, 2021</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">John W. Hadden II</TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
  
  <!-- Field: Page; Sequence: 19; Options: Last -->
      <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: center"><TD STYLE="width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "s811577016_11192021.htm", "secsgml_size_bytes": 121733}]
metadata_filer: {"company-data": {"conformed-name": "PLx Pharma Inc.", "cik": "0001497504", "assigned-sic": "2834", "irs-number": "271707962", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-261258", "film-number": "211430251"}, "business-address": {"street1": "9 FISHERS LANE", "street2": "SUITE E", "city": "SPARTA", "state": "NJ", "zip": "07871", "phone": "(713) 842-1249"}, "mail-address": {"street1": "9 FISHERS LANE", "street2": "SUITE E", "city": "SPARTA", "state": "NJ", "zip": "07871"}, "former-company": [{"former-conformed-name": "Dipexium Pharmaceuticals, Inc.", "date-changed": "20140313"}, {"former-conformed-name": "Dipexium Pharmaceuticals, LLC", "date-changed": "20100726"}]}
text: As filed with the Securities and Exchange Commission
  on November 22, 2021
  Registration No. 333-
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  ____________________________
  FORM S-8
  REGISTRATION STATEMENT
  UNDER
  THE SECURITIES ACT OF 1933
  ____________________________
  PLX PHARMA INC.
  (Exact name of registrant as specified in its charter)
  Delaware
  (State or other jurisdiction of
  incorporation or organization)
  46-4995704
  (I.R.S. Employer Identification Number)
  PLx Pharma Inc.
  9 Fishers Lane, Suite E
  Sparta, New Jersey 07871
  (Address of principal executive offices)
  ____________________________
  PLX PHARMA INC. 2018 INCENTIVE PLAN
  PLX PHARMA INC. 2015 OMNIBUS INCENTIVE PLAN
  (Full title of the plans)
  ____________________________
  Natasha Giordano
  President and Chief Executive Officer
  PLx Pharma Inc.
  9 Fishers Lane, Suite E
  Sparta, New Jersey 07871
  (973) 409-6541
  (Name, address and telephone number, including area
  code, of agent for service)
  ____________________________
  With a copy to:
  Robert Friedman, Esq.
  Olshan Frome Wolosky LLP
  1325 Avenue of the Americas
  New York, New York 10019
  Telephone: (212) 451-2300
  ____________________________
  Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
  See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company"
  and "emerging growth company" in Rule 12b-2 of the Exchange Act.
  TABLE OF CONTENTS
  Large accelerated filer
  o
  Accelerated filer
  o
  Non-accelerated filer
  ý
  Smaller reporting company
  ý
  Emerging growth company
  o
  If an emerging growth company, indicate by check mark
  if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
  provided pursuant to Section 7(a)(2)(B) of the Securities Act.
  ____________________________
  TABLE OF CONTENTS
  CALCULATION OF REGISTRATION FEE
  Title of Securities to be Registered
  Amount to be Registered
  (1)
  Proposed Maximum Offering Price Per Share
  (2)
  Proposed Maximum Aggregate Offering Price
  (2)
  Amount of
  Registration Fee
  Common Stock, par value $0.001 per share
  7,753,484
  (3)
  $10.36
  $80,326,094.24
  $7,446.23
  (1)
  Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"),
  this Registration Statement also covers such additional shares of common stock, par value $0.001 per share ("Common Stock"),
  of PLx Pharma Inc., a Delaware corporation (the "Company"), that become issuable under the plans listed in footnote 3 below
  by reason of any stock split, stock dividend, recapitalization or other similar transaction that results in an increase in the number
  of outstanding shares of Common Stock.
  (2)
  Estimated solely for the purposes of calculating the registration fee pursuant to Rules 457(c) and 457(h)
  under the Securities Act, based on the average of the high and low prices of the Common Stock as reported on the Nasdaq Global Market
  on November 19, 2021.
  (3)
  Represents 7,000,000 shares of Common Stock issuable pursuant to the PLx Pharma Inc. 2018 Incentive Plan
  (as amended, the "2018 Plan"), and 753,484 shares of Common Stock issuable pursuant to the PLx Pharma Inc. 2015 Omnibus Incentive
  Plan (as amended, the "2015 Plan").
  TABLE OF CONTENTS
  EXPLANATORY NOTE
  The Company has prepared this
  Registration Statement in accordance with the requirements of Form S-8 under the Securities Act, to register 7,753,484 shares of Common
  Stock issuable or issued pursuant to the 2015 Plan and the 2018 Plan.
  This Form S-8 includes a Reoffer
  Prospectus prepared in accordance with Part I of Form S-3 under the Securities Act. The Reoffer Prospectus may be utilized for reofferings
  and resales of shares of Common Stock acquired pursuant to the 2015 Plan and the 2018 Plan.
  PART I
  INFORMATION REQUIRED IN
  THE SECTION 10(a) PROSPECTUS
  The information required
  by Item 1 and Item 2 of Part I of Form S-8 is omitted from this filing in accordance with Rule 428 under the Securities Act and the introductory
  note to Part I of Form S-8.
  The documents containing the information in Part I
  relating to the Plans will be sent or given to participants in the Plans as specified by Rule 428(b)(1) promulgated under the Securities
  Act. In accordance with the instructions to Part I of Form S-8, such documents will not be filed with the SEC either as part of this Registration
  Statement or as prospectuses or prospectus supplements pursuant to Rule 424 promulgated under the Securities Act. These documents and
  the documents incorporated by reference pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute the prospectus
  (the "Section 10(a) Prospectus") as required by Section 10(a) of the Securities Act in respect of future issuances under the
  Plans.
  Upon written or oral request, any of the documents
  incorporated by reference in Item 3 of Part II of this Registration Statement, which are also incorporated by reference in the Section
  10(a) Prospectus, other documents required to be delivered to eligible participants pursuant to Rule 428(b), or additional information
  about the Plans, will be available without charge by contacting the Corporate Secretary at 9 Fishers Lane, Ste. E, Sparta, New Jersey
  07871 or (973) 409-6541.
  TABLE OF CONTENTS
  PROSPECTUS
  7,753,484 Shares
  PLX PHARMA INC.
  Common Stock ($0.001 par value)
  This prospectus relates to
  the reoffer and resale by certain selling stockholders of shares of PLx Pharma Inc. ("PLx Pharma", the "Company",
   "we", "our" or "us") or shares that may be issued by us to the selling stockholders upon the exercise
  of stock options granted under our 2015 Omnibus Incentive Plan (as amended, the "2015 Plan") and our 2018 Stock Incentive
  Plan (as amended, the "2018 Plan"). This prospectus also relates to certain underlying options, shares of restricted stock
  and shares relating to restricted stock units that have not as of this date been granted or issued. If and when such options, shares of
  restricted stock, or shares relating to restricted stock units are granted to persons required to use the prospectus to reoffer and resell
  the shares underlying such options, the shares of restricted stock or the shares relating to the restricted stock units, we will distribute
  a prospectus supplement. The shares are being reoffered and resold for the account of the selling stockholders and we will not receive
  any of the proceeds from the resale of the shares.
  The selling stockholders have
  advised us that the resale of their shares may be effected from time to time in one or more transactions on the Nasdaq Global Market,
  in negotiated transactions or otherwise, at market prices prevailing at the time of the sale or at prices otherwise negotiated. See "Plan
  of Distribution." We will bear all expenses in connection with the preparation of this prospectus. We will, however, receive the
  exercise price of any options, exercisable into shares that will be reoffered and resold, at the time of their exercise.
  Our common stock ("Common
  Stock") is listed on the Nasdaq Capital Market ("Nasdaq") under the symbol "PLXP". On November 19, 2021,
  the last reported sale price of our Common Stock on Nasdaq was $10.07.
  Investing in our Common
  Stock involves a high degree of risk. You should carefully review the risks and uncertainties we have described under the section titled
   "Risk Factors" on page 1 of this prospectus, and under similar sections in the other documents that are incorporated
  by reference into this prospectus, including those filed after the date hereof.
  NEITHER THE SECURITIES
  AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS
  IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
  The date of this prospectus is November 22, 2021.
  TABLE OF CONTENTS
  TABLE OF CONTENTS
  ABOUT THIS PROSPECTUS
  i
  PROSPECTUS SUMMARY
  ii
  RISK FACTORS
  1
  FORWARD-LOOKING STATEMENTS
  1
  USE OF PROCEEDS
  1
  DETERMINATION OF OFFERING PRICE
  1
  SELLING STOCKHOLDERS
  1
  PLAN OF DISTRIBUTION
  3
  LEGAL MATTERS
  5
  ADDITIONAL INFORMATION
  5
  INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
  5
  DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES
  6
  PART II  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  7
  SIGNATURES
  11
  POWER OF ATTORNEY
  11
  TABLE OF CONTENTS
  ABOUT
  THIS PROSPECTUS
  This prospectus is part of a registration statement
  on Form S-8 that we filed with the Securities and Exchange Commission ("SEC"). All references to "Company," "we,"
   "our" or "us" refer solely to PLx Pharma Inc. and not to the persons who manage us or sit on our Board of Directors
  or are our stockholders. Reference to "selling stockholders" refers to those stockholders listed herein in the section titled
   "Selling Stockholders" beginning on page 1 of this prospectus, who may sell shares from time to time as described
  in this prospectus. All trade names used in this prospectus are either our registered trademarks or trademarks of their respective holders.
  No person has been authorized to give any information
  or to make any representations other than those contained in this prospectus, and if given or made, such information or representations
  must not be relied upon as having been authorized by the Company, any selling stockholder or by any other person. Neither the delivery
  of this prospectus nor any sale made hereunder shall, under any circumstances, create any implication that information herein is correct
  as of any time subsequent to the date hereof. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy
  any security other than the securities covered by this prospectus, nor does it constitute an offer to or solicitation of any person in
  any jurisdiction in which such offer or solicitation may not lawfully be made.
  This document may only be used where it is legal
  to sell these securities. The information contained in this prospectus (and in any supplement or amendment to this prospectus) is accurate
  only as of the date on the front of the document, and any information we have incorporated by reference is accurate only as of the date
  of the document incorporated by reference, regardless of the time of delivery of this prospectus or any sale of our Common Stock. Our
  business, financial condition, results of operations and prospects may have changed since those dates.
  We urge you to read carefully this prospectus
  (as supplemented and amended), together with the information incorporated herein by reference as described in the section titled "Incorporation
  of Certain Information by Reference" before deciding whether to invest in any of the Common Stock being offered.
  This prospectus incorporates by reference market
  data, industry statistics and other data that have been obtained from, or compiled from, information made available by third parties.
  We have not independently verified their data.
  i
  TABLE OF CONTENTS
  PROSPECTUS
  SUMMARY
  This summary highlights selected information
  contained elsewhere or incorporated by reference in this prospectus. This summary may not contain all the information that you should
  consider before determining whether to invest in our securities. You should read the entire prospectus carefully, including the information
  included in the "Risk Factors" section, as well as our consolidated financial statements, notes to the consolidated financial
  statements and the other information incorporated by reference into this prospectus, as well as the exhibits to the registration statement
  of which this prospectus is a part, before making an investment decision.
  The Company
  We are a commercial-stage
  drug delivery platform technology company focused on improving how and where active pharmaceutical ingredients (APIs) are absorbed in
  the gastrointestinal (GI) tract via its clinically validated and patent protected PLxGuard™ technology. We believe this platform
  has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach
  injury associated with certain drugs.
  VAZALORE™ 325 mg and
  VAZALORE™ 81 mg (referred to together as "VAZALORE") are FDA-approved liquid-filled aspirin capsule, available in 81
  mg and 325 mg doses. VAZALORE delivers aspirin differently from plain and enteric coated aspirin products. The special complex inside
  the capsule allows for targeted release of aspirin, limiting its direct contact with the stomach. VAZALORE delivers fast, reliable absorption
  for pain relief plus the lifesaving benefits of aspirin.
  Our commercialization strategy
  targets the over-the-counter ("OTC") market, taking advantage of the existing distribution channels for aspirin. We market
  VAZALORE to the healthcare professional and the consumer through several sales and marketing channels. Our product pipeline also includes
  other oral NSAIDs using the PLxGuard drug delivery platform that may be developed, including PL1200 Ibuprofen 200 mg and PL1200 Ibuprofen
  400 mg, for pain and inflammation in Phase I clinical stage.
  We were originally incorporated
  in Texas in 2002 and re-incorporated in Delaware in 2015. On April 19, 2017, Dipexium Acquisition Corp., a Delaware corporation ("Merger
  Sub") and a wholly-owned subsidiary of Dipexium Pharmaceuticals, Inc., a Delaware corporation ("Dipexium"), merged with
  and into PLx Pharma Inc., a privately-held Delaware corporation ("Old PLx"), pursuant to the terms of that certain Agreement
  and Plan of Merger and Reorganization dated as of December 22, 2016 by and among Dipexium, Merger Sub and Old PLx (the "Merger").
  As part of the Merger, Dipexium was re-named PLx Pharma Inc. and Old PLx was re-named PLx Opco Inc. Following completion of the Merger,
  Old PLx became a wholly-owned subsidiary of the Company. Since the completion of the Merger, the business we have conducted has been primarily
  the business of Old PLx. The combined company, renamed as PLx Pharma Inc., together with its subsidiary PLx Opco Inc., is referred to
  herein as the "Company."
  The Company's headquarters
  is located at 9 Fishers Lane, Ste. E, Sparta, New Jersey 07871. Our telephone number is (973) 409-6541.
  ii
  TABLE OF CONTENTS
  RISK
  FACTORS
  Investing in our securities involves significant
  risks. Before deciding whether to invest in our securities, you should carefully consider the risks, uncertainties and assumptions described
  in this prospectus and any accompanying prospectus supplement, including the risk factors set forth in our filings with the SEC that are
  incorporated by reference herein and therein, including the risk factors in our most recent Annual Report on Form 10-K, as amended, as
  revised or supplemented by our Quarterly Reports on Form 10-Q, and which may be amended, supplemented or superseded from time to time
  by other reports we file with the SEC in the future. There may be other unknown or unpredictable economic, business, competitive, regulatory
  or other factors that could have material adverse effects on our future results. If any of these risks actually occurs, our business,
  business prospects, financial condition or results of operations could be seriously harmed. Please also read carefully the section below
  titled "Forward-Looking Statements."
  FORWARD-LOOKING
  STATEMENTS
  This prospectus and certain documents incorporated
  by reference in this prospectus contain forward-looking statements. In some cases, you can identify forward-looking statements by terms
  such as "may," "intend," "might," "will," "should," "could," "would,"
   "expect," "believe," "estimate," "predict," "potential," or the negative of
  these terms, and similar expressions. These statements reflect our current views with respect to future events. These statements involve
  known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially
  different from any future results, performances or achievements expressed or implied by the forward-looking statements, many of which
  are discussed in greater detail in the section titled "Risk Factors" in this prospectus.
  USE
  OF PROCEEDS
  The shares of Common Stock offered hereby are
  being registered for the account of the selling stockholders identified in this prospectus. The selling stockholders will receive all
  of the net proceeds from sales of the Common Stock pursuant to this prospectus. We will not receive any part of the proceeds from such
  sales of Common Stock. We will, however, receive the exercise price of the options at the time of their exercise. We expect to use any
  such proceeds primarily for working capital and general corporate purposes.
  DETERMINATION
  OF OFFERING PRICE
  The selling stockholders may sell the shares
  of our Common Stock issued to them from time to time at prices and at terms prevailing or at prices related to the current market price,
  or in negotiated transactions.
  SELLING
  STOCKHOLDERS
  This reoffer prospectus relates to the reoffer
  and resale of shares of Common Stock that have been issued or that may be issued in the future to the selling stockholders, listed below,
  or future selling stockholders under our 2015 Plan and 2018 Plan. Certain unnamed non-affiliates, each of whom may sell up to the lesser
  of 1,000 shares of Common Stock or 1% of the shares of our Common Stock issuable under the Plans may use this reoffer prospectus for reoffers
  and resales.
  The following table sets forth (i) the number
  of shares of Common Stock beneficially owned by each selling stockholder at November 16, 2021, (ii) the number of shares to be offered
  for resale by each selling stockholder (i.e., the total number of shares underlying options held by each selling stockholder irrespective
  of whether such options are presently exercisable or exercisable within sixty days of November 16, 2021), and (iii) the number and percentage
  of shares of our Common Stock to be held by each selling stockholder after completion of the offering (i.e., such number is exclusive
  of shares underlying options that have not been exercised). Except as otherwise set forth below, the address of the persons listed below
  is c/o PLx Pharma Inc., 9 Fishers Lane, Suite E, Sparta, New Jersey 07871 and each of the persons listed has, to our knowledge, sole voting
  and investment power with respect to the indicated shares of Common Stock.
  1
  TABLE OF CONTENTS
  All information with respect to the Common Stock ownership
  of the selling stockholders has been furnished by or on behalf of the selling stockholders. We believe, based on information supplied
  by the selling stockholders, that except as may otherwise be indicated in the footnotes to the table below, the selling stockholders have
  sole voting and dispositive power with respect to the Common Stock reported as beneficially owned by them. Because the selling stockholders
  identified in the table may sell some or all of the Common Stock owned by them and covered by this reoffer prospectus, and because there
  are currently no agreements, arrangements or understandings with respect to the sale of any of the Common Stock, no estimate can be given
  as to the number of Common Stock available for resale hereby that will be held by the selling stockholders upon termination of this offering.
  In addition, the selling stockholders may have sold, transferred or otherwise disposed of, or may sell, transfer or otherwise dispose
  of, at any time and from time to time, the common shares they hold in transactions exempt from the registration requirements of the Securities
  Act after the date on which they provided the information set forth in the table below. We have, therefore, assumed for the purposes of
  the following table, that the selling stockholders will sell all of the common shares owned beneficially by them that are covered by this
  reoffer prospectus, but will not sell any other common shares that they presently own.
  Name
  Relationship to the Company
  Number of shares of
  Common Stock
  Beneficially Owned at
  November 16, 2021 (1)
  Number of
  Shares to be
  Offered for
  Resale (2)
  Number of
  shares of
  Common Stock Beneficially Owned
  After
  Completion of
  the Offering (3)
  Percentage of
  Class to be
  Owned After
  Completion
  of the
  Offering
  Michael J. Valentino
  Executive Chairman of the Board of Directors
  1,061,013
  432,509
  (4)
  815,171
  2.9
  %
  Natasha Giordano
  CEO and Director
  620,655
  1,240,127
  (5)
  1,086
  *
  Rita M. O'Connor
  CFO
  242,420
  544,675
  (6)
  12,970
  *
  Gary S. Balkema
  Director
  47,779
  89,001
  (7)
  5,445
  *
  Anthony Bartsh
  Director
  —
  —
  —
  —
  Kirk Calhoun
  Director
  44,009
  89,001
  (8)
  1,675
  *
  Robert Casale
  Director
  45,044
  89,001
  (9)
  2,710
  *
  John W. Hadden II
  Director
  46,024
  89,001
  (10)
  3,690
  *
  ____________
  *
  Less than one percent
  (1)
  A person is deemed to be the beneficial owner of voting securities that can be acquired by such person within 60 days after November 16, 2021 upon the exercise of options, warrants or convertible securities.  Each beneficial owner's percentage ownership is determined by assuming that options, warrants or convertible securities that are held by such person (but not those held by any other person) and that are currently exercisable (i.e., that are exercisable within 60 days from November 16, 2021) have been exercised.  Unless otherwise noted, we believe that all persons named in the table have sole voting and investment power with respect to all shares beneficially owned by them.
  2
  TABLE OF CONTENTS
  (2)
  Includes vested and non-vested stock options.
  (3)
  Includes the aggregate ownership of the Company's Common Stock assuming all of the shares of Common Stock offered for resale pursuant to their offering have been sold.
  (4)
  Includes shares underlying 245,842 stock options that will vest within 60 days of November 16, 2021, as well as shares underlying 186,667 stock options will vest more than 60 days after November 16, 2021 held by Mr. Valentino.
  (5)
  Includes shares underlying 619,569 stock options that will vest within 60 days of November 16, 2021, as well as shares underlying 620,558 stock options that will vest more than 60 days after November 16, 2021 held by Ms. Giordano.
  (6)
  Includes shares underlying 229,450 stock options that will vest within 60 days of November 16, 2021, as well as shares underlying 315,225 stock options that will vest more than 60 days after November 16, 2021 held by Ms. O'Connor.
  (7)
  Includes shares underlying 42,334 stock options that will vest within 60 days of November 16, 2021, as well as shares underlying 46,667 stock options that will vest more than 60 days after November 16, 2021 held by Mr. Balkema.
  (8)
  Includes shares underlying 42,334 stock options that will vest within 60 days of November 16, 2021, as well as shares underlying 46,667 stock options that will vest more than 60 days after November 16, 2021 held by Mr. Calhoun.
  (9)
  Includes shares underlying 42,334 stock options that will vest within 60 days of November 16, 2021, as well as shares underlying 46,667 stock options that will vest more than 60 days after November 16, 2021 held by Mr. Casale.
  (10)
  Includes shares underlying 42,334 stock options that will vest within 60 days of November 16, 2021, as well as shares underlying 46,667 stock options that will vest more than 60 days after November 16, 2021 held by Mr. Hadden.
  PLAN
  OF DISTRIBUTION
  The selling stockholders, which as used herein
  includes donees, pledgees, transferees or other successors-in-interest, selling shares of Common Stock may, from time to time, sell, transfer
  or otherwise dispose of any or all of their shares of Common Stock or interests in shares of Common Stock on any stock exchange, market
  or trading facility on which the shares are traded or in private transactions. The selling stockholders may sell their shares of our common
  stock pursuant to this prospectus at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing
  market price, at varying prices determined at the time of sale, or at negotiated prices.
  The
  selling stockholders may use any one or more of the following methods when disposing of shares or interests therein:
  ·
  ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
  ·
  block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block
  as principal to facilitate the transaction;
  ·
  purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
  3
  TABLE OF CONTENTS
  ·
  an exchange distribution in accordance with the rules of the applicable exchange;
  ·
  privately negotiated transactions;
  ·
  short sales;
  ·
  through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
  ·
  broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;
  ·
  a combination of any such methods of sale; and
  ·
  any other method permitted pursuant to applicable law.
  The selling stockholders may effect such transactions
  by selling shares to or through broker-dealers, and all such broker-dealers may receive compensation in the form of discounts, concessions,
  or commissions from the selling stockholders and/or the purchasers of shares of Common Stock for whom such broker-dealers may act as agents
  or to whom they sell as principals, or both (which compensation as to a particular broker-dealer might be in excess of customary commissions).
  Any broker-dealer acquiring Common Stock from
  the selling stockholders may sell the shares either directly, in its normal market-making activities, through or to other brokers on
  a principal or agency basis or to its customers. Any such sales may be at prices then prevailing on Nasdaq or at prices related to such
  prevailing market prices or at negotiated prices to its customers or a combination of such methods. The selling stockholders and any
  broker-dealers that act in connection with the sale of the Common Stock hereunder might be deemed to be "underwriters" within
  the meaning of Section 2(11) of the Securities Act; any commissions received by them and any profit on the resale of shares as principal
  might be deemed to be underwriting discounts and commissions under the Securities Act. Any such commissions, as well as other expenses
  incurred by the selling stockholders and applicable transfer taxes, are payable by the selling stockholders.
  The selling stockholders reserve the right to
  accept, and together with any agent of the selling stockholder, to reject in whole or in part any proposed purchase of the shares of Common
  Stock. The selling stockholders will pay any sales commissions or other seller's compensation applicable to such transactions.
  We have not registered or qualified offers and
  sales of shares of the Common Stock under the laws of any country, other than the United States. To comply with certain states'
  securities laws, if applicable, the selling stockholders will offer and sell their shares of Common Stock in such jurisdictions only through
  registered or licensed brokers or dealers. In addition, in certain states the selling stockholders may not offer or sell shares of Common
  Stock unless we have registered or qualified such shares for sale in such states or we have complied with an available exemption from
  registration or qualification.
  The selling stockholders have represented to
  us that any purchase or sale of shares of Common Stock by them will comply with Regulation M promulgated under the Securities Exchange
  Act of 1934, as amended (the "Exchange Act"). In general, Rule 102 under Regulation M prohibits any person connected with
  a distribution of our Common Stock (a "Distribution") from directly or indirectly bidding for, or purchasing for any account
  in which he or she has a beneficial interest, any of our Common Stock or any right to purchase our Common Stock, for a period of one
  business day before and after completion of his or her participation in the distribution (we refer to that time period as the "Distribution
  Period").
  4
  TABLE OF CONTENTS
  During the Distribution Period, Rule 104 under
  Regulation M prohibits the selling stockholders and any other persons engaged in the Distribution from engaging in any stabilizing bid
  or purchasing our Common Stock except for the purpose of preventing or retarding a decline in the open market price of our Common Stock.
  No such person may effect any stabilizing transaction to facilitate any offering at the market. Inasmuch as the selling stockholders
  will be reoffering and reselling our Common Stock at the market, Rule 104 prohibits them from effecting any stabilizing transaction in
  contravention of Rule 104 with respect to our Common Stock.
  There can be no assurance that the selling stockholders
  will sell any or all of the shares offered by them hereunder or otherwise.
  LEGAL
  MATTERS
  Certain legal matters in connection with the
  issuance of the shares of Common Stock offered hereby have been passed upon for us by Olshan Frome Wolosky LLP, New York, New York.
  ADDITIONAL
  INFORMATION
  We have filed with the SEC a Registration Statement
  on Form S-8 under the Securities Act with respect to the shares offered hereby. We file annual, quarterly and current reports, proxy statements
  and other information with the SEC. The SEC maintains an Internet site at http://www.sec.gov/ that contains reports, proxy and information
  statements, and other information regarding issuers, such as us, that file electronically with the SEC. Additionally, you may access our
  filings with the SEC through our website at https://plxpharma.com/. The information on our website is not part of this prospectus.
  INCORPORATION
  OF CERTAIN INFORMATION BY REFERENCE
  The SEC allows us to incorporate by reference
  the information we file with it, which means that we can disclose important information to you by referring you to those documents. The
  information we incorporate by reference is considered to be part of this prospectus, and information that we file later with the SEC will
  automatically update and supersede this information. We incorporate by reference the documents listed below and any future filings made
  by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, until the sale of all the shares of common stock that
  are part of this offering. The documents we are incorporating by reference are as follows:
  ·
  Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2020 filed with the SEC on March 12, 2021, as amended
  by the Form 10-K/A filed with the SEC on April 30, 2021;
  ·
  Quarterly Reports on Form 10-Q the Company for the fiscal quarter ended March 31, 2021, filed with the SEC on May 14, 2021; for the
  fiscal quarter ended June 30, 2021, filed with the SEC on August 6, 2021; and for the fiscal quarter ended September 30, 2021, filed with
  the SEC on November 12, 2021;
  5
  TABLE OF CONTENTS
  ·
  Current Reports on Form 8-K of the Company filed with the SEC on January 11, 2021, March 1, 2021 (other than information furnished
  rather than filed), March 2, 2021, March 3, 2021, March 12, 2021 (other than information furnished rather than filed), March 17, 2021,
  May 14, 2021 (other than information furnished rather than filed), August 6, 2021 (other than information furnished rather than filed),
  August 6, 2021, September 21, 2021 (other than information furnished rather than filed) and November 12, 2021 (other than information
  furnished rather than filed); and
  ·
  The description of the Common Stock contained in the Company's Registration Statement on Form 8-A, declared effective by the
  SEC on March 12, 2014, including any amendments or reports filed for the purpose of updating such description.
  All documents filed pursuant
  to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of the initial registration statement and prior to effectiveness
  of the registration statement and after the date of this prospectus but prior to the filing of a post-effective amendment which indicates
  that all securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated
  by reference into this Registration Statement and to be a part hereof from the date of filing of such documents, provided, however, that
  the registrant is not incorporating any information furnished under either Item 2.02 or Item 7.01 of any Current Report on Form 8-K.
  Any document, and any statement
  contained in a document, incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for
  purposes of this prospectus to the extent that a statement contained herein, or in any other subsequently filed document that also is
  incorporated or deemed to be incorporated by reference herein, modifies or supersedes such document or statement. Any such document or
  statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.
  The documents incorporated
  by reference in this prospectus may be obtained from us without charge and will be provided to each person, including any beneficial owner,
  to whom a prospectus is delivered. You may obtain a copy of the documents at no cost by submitting an oral or written request to:
  PLx Pharma Inc.
  9 Fishers Lane, Ste. E
  Sparta, New Jersey 07871
  Attn: Corporate Secretary
  (973) 409-6541
  Additional information
  about us is available at our web site located at https://plxpharma.com/. Information contained in our web site is not a part of this prospectus.
  DISCLOSURE
  OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES
  Insofar as indemnification
  for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Company, the Company
  has been advised that it is the SEC's opinion that such indemnification is against public policy as expressed in the Securities
  Act and is, therefore, unenforceable.
  6
  TABLE OF CONTENTS
  PART
  II
  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  Item 3.
  Incorporation of Documents by Reference
  The following documents previously
  filed by the Company with the SEC under the Securities Act and the Exchange Act, are incorporated herein by reference (other than any
  such documents or portions thereof that are furnished under Item 2.02 or Item 7.01 of Form 8-K, unless otherwise indicated therein, including
  any exhibits included with such Items):
  ·
  Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2020 filed with the SEC on March 12, 2021, as amended
  by the Form 10-K/A filed with the SEC on April 30, 2021;
  ·
  Quarterly Report on Form 10-Q the Company for the fiscal quarter ended March 31, 2021, filed with the SEC on May 14, 2021; for the
  fiscal quarter ended June 30, 2021, filed with the SEC on August 6, 2021; and for the fiscal quarter ended September 30, 2021, filed with
  the SEC on November 12, 2021;
  ·
  Current Reports on Form 8-K of the Company filed with the SEC on January 11, 2021, March 1, 2021 (other than information furnished
  rather than filed), March 2, 2021, March 3, 2021, March 12, 2021 (other than information furnished rather than filed) and March 17, 2021,
  May 14, 2021 (other than information furnished rather than filed), August 6, 2021 (other than information furnished rather than filed),
  August 6, 2021, September 21, 2021 (other than information furnished rather than filed) and November 12, 2021 (other than information
  furnished rather than filed); and
  ·
  The description of the Common Stock contained in the Company's Registration Statement on Form 8-A, declared effective by the
  SEC on March 12, 2014, including any amendments or reports filed for the purpose of updating such description.
  All documents filed by the
  Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this Registration Statement (other
  than any such documents or portions thereof that are furnished under Item 2.02 or Item 7.01 of Form 8-K, unless otherwise indicated therein,
  including any exhibits included with such Items), prior to the filing of a post-effective amendment to this Registration Statement which
  indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed
  to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents.
  Any statement contained in
  this Registration Statement or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified
  or superseded for purposes of this Registration Statement to the extent that a statement contained or incorporated by reference herein
  or in any subsequently filed document that is deemed to be incorporated by reference herein modifies or supersedes such statement. Any
  such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration
  Statement.
  Item 4.
  Description of Securities
  Not applicable.
  Item 5.
  Interests of Named Experts and Counsel
  No expert or counsel named in this Registration Statement
  as having prepared or certified any part of this Registration Statement or having given an opinion upon the validity of the securities
  being registered or upon other legal matters in connection with the registration or offering of the common stock was employed on a contingency
  basis or had, or is to receive, in connection with the offering, a substantial interest, directly or indirectly, in the registrant or
  any of its parents or subsidiaries.
  7
  TABLE OF CONTENTS
  Item 6.
  Indemnification of Directors and Officers
  The Company
  may, to the fullest extent permitted by Section 145 of the Delaware General Corporation Law ("DGCL"), as the same may be amended
  and supplemented, indemnify any and all persons whom it shall have power to indemnify under said section from and against any and all
  of the expenses, liabilities, costs, fees or other matters referred to in or covered by said section, and the indemnification provided
  for shall not be deemed exclusive of any other rights to which a person indemnified may be entitled under any bylaw, agreement, insurance,
  vote of stockholders or disinterested directors or otherwise, both as to action in his official capacity and as to action in another capacity
  while holding such office, and shall continue as to a person who has ceased to be director, officer, employee or agent and shall inure
  to the benefit of the heirs, executors and administrators of such a person.
  No director
  shall be personally liable to the Company or our stockholders for monetary damages for any breach of fiduciary duty by such director as
  a director. Notwithstanding the foregoing sentence, a director shall be liable to the extent provided by applicable law: (i) for breach
  of the director's duty of loyalty to the Company or our stockholders, (ii) for acts or omissions not in good faith or which involve
  intentional misconduct or a knowing violation of law, (iii) pursuant to Section 174 of the DGCL or (iv) for any transaction from which
  the director derived an improper personal benefit.
  The Company
  is subject to Section 203 of the DGCL, which prevents an "interested stockholder" (defined in Section 203, generally, as a
  person owning 15% or more of a corporation's outstanding voting stock) from engaging in a "business combination" with
  a publicly-held Delaware corporation for three (3) years following the date such person became an interested stockholder, unless: (i)
  before such person became an interested stockholder, the board of directors of the corporation approved the transaction in which the interested
  stockholder became an interested stockholder or approved the business combination; (ii) upon consummation of the transaction that resulted
  in the interested stockholder's becoming an interested stockholder, the interested stockholder owns at least 85% of the voting stock
  of the corporation outstanding at the time the transaction commenced (subject to certain exceptions); or (iii) following the transaction
  in which such person became an interested stockholder, the business combination is approved by the board of directors of the corporation
  and authorized at a meeting of stockholders by the affirmative vote of the holders of 66% of the outstanding voting stock of the corporation
  not owned by the interested stockholder. A "business combination" includes mergers, stock or asset sales and other transactions
  resulting in a financial benefit to the interested stockholder.
  The provisions
  of Section 203 of the DGCL could have the effect of delaying, deferring or preventing a change in the control of the Company.
  The Company
  maintains a directors and officers insurance and company reimbursement policy. The policy insures directors and officers against unindemnified
  loss arising from certain wrongful acts in their capacities and reimburses the Company for such loss for which the Company has lawfully
  indemnified the directors and officers. The policy contains various exclusions, none of which relate to the offering hereunder. The Company
  also has agreements with its directors and officers providing for the indemnification thereof under certain circumstances.
  The foregoing
  summaries are qualified in their entirety by the terms and provisions of such arrangements.
  Item 7.
  Exemption From Registration Claimed
  Not applicable.
  8
  TABLE OF CONTENTS
  Item 8. Exhibits
  Exhibit
  Number
  Exhibit Description
  4.1
  Amended and Restated Certificate of Incorporation of PLx Pharma Inc., incorporated herein by reference to Exhibit 3.3 to the Company's Quarterly Report on Form 10-Q, SEC File No. 001-36351, filed on August 11, 2017.
  4.2
  Certificate of Amendment to the Amended Certificate of Incorporation of PLx Pharma Inc., incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, SEC File No. 001-36351, filed on February 20, 2019.
  4.3
  Amended and Restated Bylaws of PLx Pharma Inc., incorporated by reference to Exhibit 3.3 to the Company's Annual Report on Form 10-K, SEC File No. 001-36351, filed on January 20, 2017.
  4.4
  PLx Pharma Inc. 2015 Omnibus Incentive Plan, incorporated by reference to Annex G to the Company's Registration Statement on Form S-4, SEC File No. 333-215684, filed on January 25, 2017.
  4.5
  PLx Pharma Inc. 2018 Incentive Plan, incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q, SEC File No. 001-36351, filed on November 9, 2018.
  4.6
  PLx Pharma Inc. 2018 Incentive Plan, as amended, incorporated by reference to Annex A of the Company's Definitive Proxy Statement on Schedule 14A, SEC File No. 001-36351, filed on October 5, 2021.
  5.1
  Opinion of Olshan Frome Wolosky LLP.
  23.1
  Consent of Marcum LLP.
  23.2
  Consent of Olshan Frome Wolosky LLP (included in Exhibit 5.1).
  24.1
  Power of Attorney (included on the signature page hereto).
  9
  TABLE OF CONTENTS
  Item 9. Undertakings.
  (a)       The
  undersigned registrant hereby undertakes:
  (1)       To
  file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
  (i)       To
  include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
  (ii)       To
  reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective
  amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration
  Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
  offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
  may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
  price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration
  Fee" table in this effective Registration Statement; and
  (iii)       To
  include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any
  material change to such information in this Registration Statement;
  provided, however
  ,
  that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those
  paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to section 13 or section 15(d) of the
  Exchange Act that are incorporated by reference in this Registration Statement.
  (2)       That,
  for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new
  registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
  be the initial bona fide offering thereof.
  (3)       To
  remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
  of the offering.
  (b)       The
  undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the
  registrant's annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee
  benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration
  Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
  at that time shall be deemed to be the initial bona fide offering thereof.
  (h)       Insofar
  as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
  the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such
  indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim
  for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer
  or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer
  or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the
  matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
  by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
  10
  TABLE OF CONTENTS
  SIGNATURES
  Pursuant to the requirements of the Securities
  Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form
  S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City
  of Sparta, State of New Jersey on the 22nd day of November, 2021.
  PLX PHARMA INC.
  By:
  /s/ Natasha Giordano
  Name:
  Natasha Giordano
  Title:
  President and Chief Executive Officer
  POWER
  OF ATTORNEY
  KNOW ALL MEN BY THESE PRESENTS, that each person
  whose signature appears below constitutes and appoints Natasha Giordano and Rita O'Connor as his or her true and lawful attorney-in-fact,
  each acting alone, with full power of substitution and resubstitution for him or her and in his or her name, place and stead, in any and
  all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and to file the same,
  with exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and
  confirming all that said attorneys-in-fact or their substitutes, each acting alone, may lawfully do or cause to be done by virtue hereof.
  Pursuant to the requirements of the Securities
  Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.
  Signature
  Title
  Date
  /s/ Natasha Giordano
  President, Chief Executive Officer and Director (Principal Executive Officer)
  November 22, 2021
  Natasha Giordano
  /s/ Rita O'Connor
  Chief Financial Officer (Principal Financial and Accounting Officer)
  November 22, 2021
  Rita O'Connor
  /s/ Michael J. Valentino
  Director and Executive Chairman of the Board
  November 22, 2021
  Michael J. Valentino
  /s/ Gary Balkema
  Director
  November 22, 2021
  Gary Balkema
  /s/ Anthony Bartsh
  Director
  November 22, 2021
  Anthony Bartsh
  /s/ Robert Casale
  Director
  November 22, 2021
  Robert Casale
  /s/ Kirk Calhoun
  Director
  November 22, 2021
  Kirk Calhoun
  /s/ John W. Hadden II
  Director
  November 22, 2021
  John W. Hadden II
  11